CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Interested in new trials?
Get alerts for new trials in your area by subscribing now
FH-FOLR1 Chimeric Antigen Receptor T Cell Therapy for Treating Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia
Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis
What is CAR-T cell therapy, and how does it work?
T cells are the immune system's soldiers, but cancer cells learn to hide from them. CAR T cell therapy fixes that by adding a synthetic receptor, the chimeric antigen receptor, that lets T cells lock onto a specific target on the cancer's surface. The process has four steps: your T cells are collected through a procedure similar to blood donation; they are shipped to a manufacturing facility and engineered, which takes two to four weeks; you receive a short course of chemotherapy to make room for the new cells; then the CAR T cells are infused once, and they multiply inside your body and hunt the target. Because the cells are alive and can persist for years, a single infusion can keep working long after treatment.
Seven CAR T products are approved by the FDA: five that target CD19 for B cell leukemia and lymphomas, and two that target BCMA for multiple myeloma. Trials now aim at making CAR T work in more diseases and making it safer. For the wider cancer picture, see our cancer treatment guide.
Types of CAR-T cell therapy clinical trials
Blood cancer trials, earlier in treatment. Approved CAR T products started as a last resort. Trials now test them as second line therapy, or even first line in high risk disease, and compare them head to head against transplant or newer antibodies.
New targets and new cancers. Trials of CAR T cells aimed at proteins other than CD19 and BCMA, for T cell leukemias, Hodgkin lymphoma, and other blood cancers with no approved CAR T.
Solid tumor trials. The hardest problem. Solid tumors hide behind physical barriers and suppress immune cells. Early phase studies test CAR T in brain tumors, sarcomas, lung, ovarian, and gastrointestinal cancers, often with engineering tricks to help the cells survive inside a tumor.
Autoimmune disease trials. The most watched new area. CAR T cells that remove B cells have put patients with severe lupus, myositis, and systemic sclerosis into remission without ongoing medication in early studies. Trials in multiple sclerosis, rheumatoid arthritis, and myasthenia gravis are recruiting.
Off the shelf and faster CAR-T. Trials of CAR T cells made from healthy donors rather than the patient, which could cut the wait from weeks to days, and of manufacturing methods that produce cells in a day or two.
Safety and side effect studies. Trials testing ways to prevent or treat cytokine release syndrome, reduce infections, and manage long term effects, plus registries following people for 15 years after treatment.
Who can participate in CAR-T cell therapy trials?
Most CAR T trials require a specific diagnosis with a confirmed target protein on the cancer cells, and a treatment history, often disease that has come back or not responded after one or more prior therapies. Because the treatment is intense, studies also require adequate heart, kidney, liver, and lung function, no active serious infection, and enough time since previous treatments. Autoimmune trials usually enroll people whose disease is severe and has not responded to several standard medicines. Solid tumor and off the shelf trials are early phase and enroll small, carefully selected groups. A few studies enroll healthy donors for cell collection. Eligibility always varies by study, and CAR T trials tend to have longer eligibility lists than most.
What happens if CAR T cell therapy fails?
It depends on why. If the cancer returns without the target protein, another CAR T aimed at the same target will not work, but bispecific antibodies, other targeted drugs, or a different CAR T target may. If the cells did not persist, a second infusion or a different product is sometimes possible. Many people whose CAR T fails are eligible for clinical trials of the next generation of these treatments, which is a large part of what is recruiting now.
How long does CAR T cell therapy take?
About one to two months from start to finish. Cell collection takes a few hours. Manufacturing takes two to four weeks. Then a few days of chemotherapy, a single infusion, and typically two to four weeks of close monitoring near the treatment center. Recovery of blood counts and immune function can take months.
Do CAR-T cell therapy trial participants get paid?
Some studies offer compensation for time and travel, and study related care, including the CAR T product itself and required hospital monitoring, is typically provided at no cost to participants. Compensation varies by trial and is always described during the informed consent process before you agree to anything.
Curious whether clinical trials pay participants? Here's how compensation actually works.
How to enroll in a CAR T cell therapy clinical trial
Identify your trial. Use the filters to combine your diagnosis with CAR T cell therapy. Titles name the disease, the target (CD19, BCMA, or a newer one), and the setting, such as "relapsed or refractory" or "second line."
Check the location. CAR T is given at certified treatment centers with intensive care available, and most trials require staying near the center for about four weeks after infusion. Some sponsors help with travel and lodging; the study details say so.
Complete the health profile. Click "Get started" to begin the 5-step application. Have three things ready: your exact diagnosis and any test showing the target protein, the list of treatments you have had and how your disease responded, and your most recent organ function results if you know them.
Submit the application. A study coordinator reviews it and contacts you. Nothing is decided until you have gone through informed consent, which for CAR T is detailed and covers the risks above, and participation is voluntary at every step. Your oncologist or rheumatologist stays involved.